IN line with the resolve to offer the most advanced fertility treatment services to Nigerians, Nordica Fertility Center, Lagos and Asaba, is enhancing fertility treatment initiatives and options in the country. As part of this drive, the facility is set to relaunch its acclaimed Fertility Treatment Support Foundation (FTSF) initiative.

Nordica Lagos/Asaba – branches of the world famous Scandinavian Nordica Fertility institutions renowned for their exploits and advancements in fertility research, have been at the forefront of tackling infertility as a socio-medical problem which places a lot of strain on emotions as well as relationships.

FTSF, (formerly called the Expanding Access to Reproductive Treatment, EART) was originally introduced by Nordica Lagos in 2008 as a response to the prevalence of infertility within the Nigerian society.

At that point in time, the health facility offered 16 Nigerian couples across the Federation, opportunity to access series of free In-vitro Fertilisation (IVF) cycles under FTSF initiative – then known as the Expanding Access to Reproductive Treatment (EART) Programme.

The FTSF initiative was put together as a platform for enabling all fertility-challenged Nigerian couples, to have access to the best and most advanced Assisted Fertility Treatment services in the world, at no cost

Two specially selected couples who ultimately emerged from the raffle draw, benefitted from novel initiatives. From research, one out of every four Nigerian couples is fertility-challenged. To keep the dream of fertility-challenged couples alive, FTSF was born.

In the last seven years,Nordica Lagos/Asaba has pioneered (in Nigeria) series of acclaimed fertillty-enhancing initiatives from Laser Hatching technology to the Intra-Cytosplasmic Morphologically-Selected Sperm Injection (IMSI) – a technique that enables the direct selection of good sperms from the man and then injecting into the woman’s egg to successfully achieve pregnancy.

Affiliated with Nordica International of Denmark, the centre has access to research findings from The Institute of Human Reproduction Symbion, Fruebjerguej, Denmark (a research centre) and The Fertility Clinic of Copenhagen University at Herlev Hospital, Copenhagen Denmark.


Comments expressed here do not reflect the opinions of vanguard newspapers or any employee thereof.